[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fungal-infection-lungs\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fungal-infection-lungs":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":36,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":66},"100645390","derivation-and-validation-of-the-fungal-pneumonia-assessment-and-likelihood-predictor-score-100645390",false,"NCT07681583","Derivation and Validation of the Fungal Pneumonia Assessment and Likelihood Predictor Score","FUNGAL-P","Inclusion Criteria:\n\n* Age ≥18 years and ≤90 years.\n* Presentation to the Emergency Department or hospital with pneumonia.\n* Pneumonia defined according to IDSA\u002FATS criteria as the presence of at least two clinical signs or symptoms of lower respiratory tract infection (temperature \\\u003C36.0°C or \\>38.0°C, respiratory rate \\>20 breaths\u002Fmin, oxygen saturation \\\u003C90% on room air, arterial PaO₂ \\\u003C60 mmHg, cough, sputum production, white blood cell count \\\u003C4,000\u002FμL or \\>10,000\u002FμL, or bandemia \\>10%) together with radiographic evidence of a new pulmonary infiltrate or cavitary lesion.\n* Bronchoalveolar lavage (BAL), bronchial aspirate (BAS), or endotracheal aspirate (ETA) performed within 48 hours of hospital presentation.\n* Modified Rankin Scale score \\\u003C5.\n* Availability of microbiological investigations for identification of fungal, bacterial, or viral pathogens.\n* Provision of informed consent, when required by applicable regulations and ethics committee approval.\n\nExclusion Criteria:\n\n* Refusal or withdrawal of informed consent.\n* Age \\\u003C18 years or \\>90 years.\n* Pregnancy.\n* Expected life expectancy \\\u003C3 months.\n* Hospital-acquired pneumonia with onset \\>48 hours after hospital admission.\n* Modified Rankin Scale score ≥5.\n* Absence of microbiological diagnostic evaluation.\n* No identified bacterial, fungal, or viral pathogen after microbiological investigations.","ALL","18 Years","90 Years",{"count":20,"type":21},400,"ESTIMATED","30 Days","OBSERVATIONAL","The FUNGAL-P study is a single-center observational study designed to derive and validate a clinical prediction score for the early identification of fungal pneumonia in adult patients presenting with pneumonia.\n\nThe study includes a retrospective derivation cohort and a prospective validation cohort of patients undergoing microbiological evaluation of lower respiratory tract samples. Clinical, laboratory, radiological, microbiological, and treatment-related variables associated with fungal pneumonia will be analyzed to identify independent predictors of fungal infection. These predictors will be combined to develop the FUNGAL-P score.\n\nThe derived score will subsequently be evaluated in a prospective validation cohort to assess its diagnostic performance, calibration, and clinical utility. The ultimate goal is to facilitate earlier recognition of fungal pneumonia and support timely diagnostic testing and antifungal treatment in patients presenting to the Emergency Department or hospital with pneumonia.",[26,27,28,29,30,31,32,33,34,35],"Pneumonia","Fungal Pneumonia","Aspergillosis Pneumonia","Pulmonary Aspergillosis","Pulmonary Aspergillosis Invasive","Pneumocystis","Pneumocystis Pneumonia","Fungal Disease","Fungal Infection","Fungal Infection Lungs",[27,37,29,38,32,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53],"Aspergillus","Pneumocystis jirovecii","Coinfection","Community-Acquired Pneumonia","CAP","Risk Prediction","Clinical Prediction Rule","Clinical Risk Score","FUNGAL-P Score","SCORE","Bronchoalveolar Lavage","Emergency Department","Internal medicine","Infectious disease","Diagnostic Accuracy","Risk Factors","Respiratory Infection","RECRUITING","2026-06-26",{"date":57,"type":58},"2026-07-02","ACTUAL",{"date":60,"type":58},"2025-11-13",{"date":62,"type":21},"2031-11-13",{"name":64,"class":65},"Azienda Ospedaliero-Universitaria Careggi","OTHER",1,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":66},"100618928","fungal-empyema-thoracis-100618928","NCT07337993","Fungal Empyema Thoracis","Efficacy of Pleural Lavage With Antifungals in the Management of Fungal Empyema Thoracis: A Prospective Cohort Study","Inclusion Criteria:\n\n* All age patients with confirmed fungal empyema thoracis.\n* Patients with adequate pleural drainage through an intercostal chest tube.\n* Patients receiving systemic antifungal therapy.\n* Patients either:\n\n  1. scheduled for surgical decortication but undergoing lavage as a preoperative adjunct, or\n  2. considered unfit for surgery and managed conservatively.\n\nExclusion Criteria:\n\n* Bacterial empyema without fungal growth.\n* Known hypersensitivity to anti-fungals.\n* Severe hepatic impairment (Child-Pugh class C) contraindicating voriconazole.\n* Pregnancy or lactation.\n* Refusal to participate.",{"count":75,"type":21},50,"INTERVENTIONAL",[78],"NA","Background:\n\nFungal empyema thoracis is a rare but life-threatening pleural infection caused by fungal organisms such as Aspergillus and Candida species. It typically occurs in immunocompromised or debilitated patients and carries a high mortality rate. Conventional management involves systemic antifungal therapy and surgical decortication; however, many patients are unfit for surgery due to poor clinical status or multiple comorbidities. The use of local intrapleural antifungal therapy remains poorly studied.\n\nObjective:\n\nThis study aims to evaluate the efficacy and safety of pleural lavage with voriconazole in patients with fungal empyema thoracis, both as a pre-surgical adjunct and as a palliative measure for patients who cannot undergo surgery.\n\nMethods:\n\nA prospective cohort study will be conducted at the Department of Thoracic Surgery, Services Hospital, Lahore. Patients diagnosed with fungal empyema confirmed by pleural fluid culture or cytology will be included. Through an indwelling chest tube, voriconazole (200 mg in 100 mL normal saline) will be instilled into the pleural cavity once daily for three consecutive days. Patients will be assessed for improvement in clinical symptoms, radiological clearance, reduction in fungal load, and the need for surgical intervention. Data will be statistically analyzed to determine treatment response and safety outcomes.\n\nConclusion:\n\nPleural lavage with voriconazole offers a promising, minimally invasive approach for managing fungal empyema thoracis. If proven effective, this method could serve as a valuable addition to current antifungal strategies, improving outcomes for critically ill patients who are not candidates for surgery.",[81,35,82],"Pyothorax","Pleural Empyema",[84,85,86],"Fungal Pyothorax","pleural lavage","anti-fungals","2026-01-03",{"date":89,"type":58},"2026-01-13",{"date":91,"type":58},"2025-07-01",{"date":93,"type":21},"2027-03-31",{"name":95,"class":65},"University of Health Sciences Lahore"]